Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Raw Materials: 2012-2018

Historic Raw Materials for Lifecore Biomedical (LFCR) over the last 7 years, with Nov 2018 value amounting to $14.6 million.

  • Lifecore Biomedical's Raw Materials rose 10.42% to $14.6 million in Q4 2018 from the same period last year, while for Nov 2018 it was $14.6 million, marking a year-over-year increase of 10.42%. This contributed to the annual value of $15.3 million for FY2018, which is 50.48% up from last year.
  • According to the latest figures from Q4 2018, Lifecore Biomedical's Raw Materials is $14.6 million, which was up 5.15% from $13.9 million recorded in Q3 2018.
  • In the past 5 years, Lifecore Biomedical's Raw Materials registered a high of $15.3 million during Q2 2018, and its lowest value of $4.2 million during Q4 2016.
  • Over the past 3 years, Lifecore Biomedical's median Raw Materials value was $11.5 million (recorded in 2016), while the average stood at $11.5 million.
  • In the last 5 years, Lifecore Biomedical's Raw Materials tumbled by 62.27% in 2016 and then spiked by 215.73% in 2017.
  • Lifecore Biomedical's Raw Materials (Quarterly) stood at $12.1 million in 2014, then fell by 8.15% to $11.1 million in 2015, then tumbled by 62.27% to $4.2 million in 2016, then skyrocketed by 215.73% to $13.2 million in 2017, then increased by 10.42% to $14.6 million in 2018.
  • Its Raw Materials stands at $14.6 million for Q4 2018, versus $13.9 million for Q3 2018 and $15.3 million for Q2 2018.